SOX17 integrates HOXA and arterial programs in hemogenic endothelium to drive definitive lympho-myeloid hematopoiesis

Ho Sun Jung,Gene Uenishi,Mi Ae Park,Peng Liu,Kran Suknuntha,Matthew Raymond,Yoon Jung Choi,James A. Thomson,Irene M. Ong,Igor I. Slukvin
DOI: https://doi.org/10.1016/j.celrep.2021.108758
IF: 8.8
2021-02-01
Cell Reports
Abstract:SOX17 has been implicated in arterial specification and the maintenance of hematopoietic stem cells (HSCs) in the murine embryo. However, knowledge about molecular pathways and stage-specific effects of SOX17 in humans remains limited. Here, using SOX17-knockout and SOX17-inducible human pluripotent stem cells (hPSCs), paired with molecular profiling studies, we reveal that SOX17 is a master regulator of HOXA and arterial programs in hemogenic endothelium (HE) and is required for the specification of HE with robust lympho-myeloid potential and DLL4<sup>+</sup>CXCR4<sup>+</sup> phenotype resembling arterial HE at the sites of HSC emergence. Along with the activation of NOTCH signaling, SOX17 directly activates CDX2 expression, leading to the upregulation of the <em>HOXA</em> cluster genes. Since deficiencies in HOXA and NOTCH signaling contribute to the impaired <em>in vivo</em> engraftment of hPSC-derived hematopoietic cells, the identification of SOX17 as a key regulator linking arterial and HOXA programs in HE may help to program HSC fate from hPSCs.
cell biology
What problem does this paper attempt to address?